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The focus of CML treatment is shifting to dose management, with the goal of maintaining 
response while improving quality of life. Results obtained from dasatinib dose optimization and 
discontinuation trials will help practitioners determine the best dose and duration of dasatinib for 
patients with CML.  
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Chronic myeloid leukemia (CML) has evolved into a chronic disease managed with tyrosine 
kinase inhibitor (TKI) therapy. Now that long-term survival has been achieved in CML, the focus 
of treatment shifts to dose optimization, with the goal of maintaining response while improving 
quality of life. In this review, we discuss optimizing the dose of the second-generation TKI 
dasatinib. Once-daily dosing regimens for dasatinib in the first and later lines of treatment were 
established through long-term (5- and 7-year) trials. Recently published data indicate that 
further dose optimization may maintain efficacy while minimizing adverse events. Results 
obtained from dose optimization and discontinuation trials currently in progress will help 
practitioners determine the best dose and duration of dasatinib for patients with CML, as 
treatment decisions will be made through continued discussions between physicians and 
patients.  
 
KEYWORDS: Dasatinib; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Quality of life;  
Tyrosine kinase inhibitor; Dose optimization
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Chronic myeloid leukemia (CML) has evolved into a chronic disease now managed with tyrosine 
kinase inhibitor (TKI) therapy.1,2 As a result of the use of TKIs approved for CML, patients 
diagnosed in 2013 are predicted to lose < 3 life-years compared with those without CML, and 
thus have life spans approaching those of the general population.3,4 In the United States, rates 
for new CML cases have been stable over the past 10 years; however, death rates have been 
decreasing an average 3.1% each year over 2004 through 2013 (Fig. 1).5 Sixty-five percent of 
patients with CML survived 5 years or more during 2006 through 2012, as opposed to the 5-
year period ending in 2000, when < 50% of patients survived 5 years or more. 
Now that long-term survival has been achieved in CML, the focus of treatment shifts to dose 
optimization and personalization. Dasatinib is a second-generation BCR-ABL1 kinase inhibitor, 
currently approved at 2 doses6: at 100 mg once daily for patients with CML in chronic phase 
(CML-CP), newly diagnosed or following resistance or intolerance to a previous therapy, and at 
140 mg once daily for patients with CML in accelerated/blast phase (CML-AP/BP) or with 
Philadelphia chromosome-positive (Ph+) acute lymphocytic leukemia who are resistant or 
intolerant to prior therapy. Optimization of dasatinib dosing should have 2 goals: maintenance of 
cytogenetic and molecular responses, and minimization of adverse events (AEs). In particular, 
optimization should describe the minimum daily dose of dasatinib that can sustain remission 
and achieve a patient’s therapeutic goals.  
Maintaining or improving quality of life (QoL) for patients with CML over the course of their 
treatment should be a major part of minimizing AEs. QoL may influence a patient’s decision to 
seek treatment regimens of dasatinib that balance efficacy with the fewest AEs, and also offer 
the easiest adherence.7 For example, a drug taken once per day is preferable to one requiring 
multiple daily doses, and a drug that may be taken regardless of type or timing of food is 
preferable to one that requires timing with regard to meals or that cannot be taken with certain 
foods. Younger female patients with CML treated with imatinib have reported lower QoL than 
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the general population8; this finding implies that for those who anticipate being on a TKI for 
many years, QoL aspects of treatment may be especially important. 
Ongoing studies are helping to refine treatment options that may be appropriate for some 
patients, including dasatinib dose reductions, interruptions, or discontinuation. It is the goal of 
this review to bring clarity to the field of dasatinib dose optimization by discussing published 
retrospective analyses and ongoing prospective studies. In particular, we discuss factors that 
drive selection of the optimal dasatinib dose and duration for the treatment of CML. 
 
OPTIMIZING CURRENTLY APPROVED DOSES FOR DASATINIB 
The currently approved doses of dasatinib resulted from 2 long-term pivotal trials aimed at 
maximizing efficacy while minimizing AEs. The CA180-034 trial enrolled patients with imatinib-
resistant or -intolerant CML-CP.9 This study compared dasatinib 100 or 140 mg per day, and 
once- or twice-daily schedules, to determine the optimal dosage and regimen. Results showed 
that dasatinib treatment at a dose of 100 mg once daily demonstrated durable efficacy and a 
tolerable long-term safety profile. The data obtained from this study should be considered the 
proof of principle that the daily dose of dasatinib can be lowered, from 70 mg twice per day (a 
total dose of 140 mg per day) to 100 mg once per day in particular, while maintaining efficacy in 
patients intolerant of or resistant to imatinib. 
The CA180-056 DASISION trial (Dasatinib Versus Imatinib Study in Treatment-Naïve 
Chronic Myeloid Leukemia Patients) was a study of newly diagnosed patients with CML-CP who 
received dasatinib 100 mg once daily or imatinib 400 mg once daily for a minimum of 5 years.10 
At the end of DASISION, dasatinib 100 mg once daily continued to show improved efficacy 
compared with imatinib 400 mg daily in the first line. The safety profile of first-line dasatinib            
100 mg once daily was well tolerated over the long term; no new safety signals were reported. 
Taken together, the results of DASISION confirmed that 100 mg once daily constitutes an 
optimal dose of dasatinib for patients newly diagnosed with CML-CP. 
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DASATINIB DOSE REDUCTIONS AND/OR INTERRUPTIONS 
Efficacy and Safety 
There are published data indicating that modifying the dasatinib dose from 100 mg once daily 
can mitigate significant AEs yet maintain efficacy over the long term. In the phase II DARIA-01 
study, patients with CML-CP were enrolled to determine factors influencing adherence and 
efficacy when AEs from dasatinib were managed with dose modifications.11 Patients had their 
dasatinib doses reduced from 100 mg per day to 50 mg per day when they experienced a grade 
2 or worse nonhematologic AE or grade 3 or worse hematologic AE. In this small study, 25% of 
patients had their doses reduced in the first 3 months, and 34% had their doses reduced in the 
first 6 months. At 6 months, 25 patients (78%) achieved complete cytogenetic responses 
(CCyR) and 13 (40%) achieved a major molecular response (MMR). Additionally, pleural 
effusions were managed effectively through dose modifications while molecular responses were 
maintained. In a small phase II study, NordCML006, 9 patients who had dasatinib doses 
reduced (6 to an average of 50 mg per day and 3 to an average of 63 mg per day) had nearly 
the same median rate of molecular response with 4.5-log reduction of BCR-ABL1 transcripts 
(MR4.5) as did the 8 patients who were maintained on 100 mg per day (P = .53).12 
Previously, a retrospective analysis of exposure and response to dasatinib in the CA180-
034 trial showed that major cytogenetic response (MCyR) was significantly associated with 
average steady-state dasatinib plasma concentrations.13 Reducing the daily dose from 70 mg 
twice daily to 100 mg once daily minimized AEs while maintaining efficacy by exploiting 
differences in measures of exposure: the 100 mg once-daily arm had the lowest steady-state 
trough concentration of the 4 dose arms investigated in CA180-034. Although this arm also had 
the lowest weighted average steady-state dasatinib plasma concentration, it had the highest 
dose maintenance and efficacy. Moreover, pleural effusion was significantly associated with 
trough concentration, and thus occurred the least in the 100 mg once-daily arm.  
Page 7 of 74 Cancer











The first-line OPTIMDASATINIB (Optimized Tyrosine Kinase Inhibitors Monotherapy) 
trial is currently the only prospective study of dose optimization based on therapeutic drug 
monitoring.14 This is a phase II trial with 289 newly diagnosed patients with CML-CP enrolled to 
validate a dose-optimization strategy using plasma levels of dasatinib. As part of the study, 
patients with high minimal plasma concentrations (Cmin ≥ 3 nmol/L) had their dasatinib doses 
reduced in 20-mg decrements every 15 days to 40 mg per day (if needed) in order to lower Cmin 
to < 3 nmol/L. Preliminary results of OPTIMDASATINIB showed that patients allocated to this 
therapeutic drug monitoring strategy showed reduced risk of pleural effusion without impairment 
of the kinetics of response. By 24 months, 88% of the patients with high Cmin values who then 
had their dasatinib doses lowered achieved MMR, 69% achieved molecular response with 4-log 
reduction of BCR-ABL1 transcripts (MR4.0), and 39% achieved MR4.5, considered a complete 
molecular response/remission (CMR). Moreover, the dose-optimization strategy reduced the 
risk of pleur l effusion in the study population, consistent with the data obtained by Wang et al 
in their retrospective analysis described above.13,14  
Intermittent dosing with dasatinib has been shown to improve tolerability in patients with 
CML who were resistant to or intolerant of imatinib.15 A strategy of 3 to 5 days of dasatinib, 
followed by 2 to 4 days of no drug, reduced toxicity while maintaining efficacy. Overall, 18 of 31 
patients (58%) maintained or had improved response while on weekly treatment, and 16 of 18 
(89%) achieved MMR or MR4.5. A larger study wherein 176 patients with CML received reduced 
and/or interrupted dosing of dasatinib or nilotinib showed there was no statistically significant 
difference between rates of MCyR or CCyR.16 The median lowest dasatinib doses given in        
this study were 60 mg per day for patients with CML-CP and 80 mg per day for patients with 
CML-AP.  
In addition, several case reports have corroborated the results of the previously 
discussed studies. In one report, a patient aged 85 years was successfully treated with 20 mg of 
dasatinib twice weekly after developing liver dysfunction on imatinib and achieved MMR 24 
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months later.17 In another report, 2 patients with CML-CP were treated with 20 to 50 mg per day 
of dasatinib; 1 maintained undetectable BCR-ABL1 transcripts for up to 1 year and 1 had levels 
of BCR-ABL1 transcripts 4 to 5 logs reduced (at times the levels were undetectable).18 
 
Predicting Which Patients Will Benefit From Dose Reductions 
Early molecular responses to a TKI (within the first 6 months of initiating treatment) are 
predictive of long-term outcomes in CML, and several studies have shown that TKIs induced 
fast and deep molecular responses, defined as MR4.0 or even MR4.5.19-21 These levels of 
responses predict durable, stable responses, and are considered prerequisites for either dose 
reductions or dose interruptions.  
Both the European LeukemiaNet (ELN) and National Comprehensive Cancer Care 
Network (NCCN) recommendations define optimal responders in terms of molecular 
responses.19,22,23 Therefore, at least for some patients, if deep molecular responses (MR4.0 or 
MR4.5) have been achieved after a treatment period, it should be possible to reduce dasatinib 
doses (Fig. 2).19 However, molecular monitoring at fixed intervals is recommended by both the 
NCCN (every 3-6 months 2 years after the achievement of CCyR)22 and the ELN (after the 
achievement of MMR),23 which may result in missing the optimal time to reduce doses of 
dasatinib. For example, if a deep response occurs early in this timeframe between tests, the 
opportunity for a dose reduction may be missed or delayed. 
Final study results from the 5-year DASISION trial for patients with CML-CP who 
received first-line dasatinib confirmed that achieving an early molecular response, BCR-ABL1   
≤ 10% International Scale (IS) at 3 months, was correlated with significantly higher progression-
free survival (PFS) and overall survival (OS) rates (88.9% and 93.8%, respectively, for PFS and 
OS) compared with patients who achieved BCR-ABL1 > 10% (IS) at 3 months (71.8% and 
80.6%, respectively, for PFS and OS).10 For patients who received dasatinib after failing or 
becoming intolerant to imatinib in the 7-year CA180-034 study, those who achieved BCR-ABL1 
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≤ 10% (IS) at 3 months likewise showed significantly higher PFS and OS (56% and 72%, 
respectively, for PFS and OS) than those who had BCR-ABL1 > 10% (IS) at 3 months (21% and 
56%, respectively, for PFS and OS).9 
Tools predicting outcome at any time during and after therapy would be useful 
throughout a patient’s treatment regimen. Using data from DASISION and CA180-034,9,10 
investigators predicted responses during treatment with dasatinib based on plotting BCR-ABL1 
transcript levels and PFS or OS of patient populations.24 Such analyses may allow investigators 
to predict future outcomes at any time, rather than solely at times of BCR-ABL1 monitoring. A 
limitation of these projections would be that they become less precise as more time elapses 
from initiation of TKI therapy: the number of patients for whom a prediction might be made 
diminishes, reducing the accuracy of the prediction. Increasing the number of patients in the 
cohort is one way to negate this limitation, for example by combining suitable datasets.  
In addition to molecular responses, effects on CD34+ cells may provide another means 
to predict responses to dasatinib. A study of newly diagnosed patients with CML-CP showed 
that the molecular responses at 3 and 6 months depended on the time of dasatinib plasma 
levels above the IC50 for CD34+ cells (dasatinib concentration required to inhibit 50% of CD34+ 
cells).25 It was found that patients with longer times (> 12 hours) above the IC50 had significantly 
better prognoses: molecular responses at 3 and < 4 log reductions were 50% and 45%, 
respectively.  
 
Other Patient Factors 
Patient preference should be taken into consideration when deciding to modify dasatinib doses. 
Reductions and/or interruptions may be preferred by patients when discontinuing dasatinib is 
not an option; administering a lower dose of dasatinib, after starting treatment at the approved 
dose, may be preferable to switching to another TKI.16 Moreover, modifying doses (lowering or 
interrupting) to mitigate toxicity may help improve adherence.11 
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In addition to minimizing AEs, economic concerns may drive a decision to lower daily 
doses for some patients.26 In one study, 41 patients with CML-CP were treated with a mean 
dose of dasatinib of 92 mg ± 23 mg per day while achieving and maintaining efficacy, although 
the quality of the responses was not reported.26 The driving force for reducing doses in this 
study appears to have been financial, rather than reduction of AEs. Furthermore, as long-term 
survival of patients with CML is predicted to increase the prevalence of the disease in the near 
future, the burden of healthcare costs may have to be considered when planning treatment. 
Thus, economic considerations beyond the personal may play a role in seeking the lowest 
effective dose of dasatinib or of any TKI.27 Many of these cost concerns may be mitigated in the 
future, as approved generic versions of TKIs become available. 
 
Ongoing Trials Investigating Dasatinib Efficacy With Dose Optimization 
Nine trials are currently under way, focusing on modifying dasatinib dosing while retaining 
efficacy; their full titles, registry numbers, and summaries are given in Table 1. Two of these 
studies, DARIA-0111 and OPTIMDASATINIB,28 and have reported preliminary data and are 
described above.  
There are 4 studies under way to determine optimizing dasatinib doses in patients or 
patient subgroups. A low-dose study in Japan will evaluate efficacy of 50 mg dasatinib per day 
in patients who are resistant to or intolerant of low-dose imatinib; the primary outcome measure 
is MMR at 12 months.29 The CML12 DIRECT (Dasatinib Intensity Regulation to Eliminate 
Cumulative Toxicities) study will examine dose optimization of dasatinib in patients 60 years and 
older with CML. In this study, therapeutic daily monitoring will be used to optimize effective 
doses with minimal toxicity.30 The DESTINY (De-Escalation and Stopping Treatment of Imatinib, 
Nilotinib or sprYcel) trial will evaluate efficacy at 50 mg per day of dasatinib in treatment-naive 
patients with CML-CP31; its primary outcome is the proportion of patients who maintain MMR on 
50 mg per day for 12 months. Patients will then discontinue dasatinib for up to 24 months. The 
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Therapy of Early Chronic Phase Chronic Myelogenous Leukemia With Dasatinib trial will 
evaluate whether giving 50 mg dasatinib per day to patients with early CML-CP is as effective 
as giving 100 mg per day.32  
Two studies will examine dasatinib efficacy with planned dose interruptions. The 
DasaHIT trial will evaluate dasatinib holidays for improved drug tolerance in treatment-naive 
patients with CML and in patients receiving dasatinib as second-line treatment; its primary 
outcome measures are cumulative toxicity after 2 years and MMR as assessed by monitoring 
BCR-ABL1 transcripts at 2 years.33 The Optimization of TKIs Treatment and Quality of Life trial 
will evaluate the efficacy of intermittent dasatinib dosing (1 month on, 1 month off vs 1 month 
on, 1 month off in year 1; 1 month on, 2 months off in year 2; 1 month on, 3 months off in year 
3), and the effect on QoL such dosing regimens may have; the primary outcome is changes in 
QoL at defined times.34  
Finally, the DasPAQT (Treating Patients With Chronic Myeloid Leukemia in Chronic Phase 
With Dasatinib) trial is a real-life study to gather data on how CML is managed with dasatinib in 




Treatment-free remission (TFR), defined as being free from molecular relapse following TKI 
discontinuation,22 is currently an unmet need of CML therapy, as TKIs have increased patients’ 
life spans to be nearly equal to those of the general population.3,4 To date, there are limited 
published data on discontinuing dasatinib. In 1 small trial of 34 patients with CML-CP, second-
generation TKIs (dasatinib and nilotinib) were safely discontinued.36 The 12-month probability of 
maintaining stable MMR was 58%, and no patient progressed to CML-AP or experienced 
hematologic relapse. The OPTIMDASATINIB trial for newly diagnosed patients with CML also 
examined dose discontinuations in early responders (those who had BCR-ABL1 [IS] ≤ 0.0032% 
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by 3 years).37 Preliminary results showed that at 12 months, 41% of patients were in TFR. The 
DADI trial evaluated the effect of dasatinib discontinuation in patients with CML who had been in 
deep molecular response for at least 1 year.38 Preliminary results showed that of the 63 patients 
who discontinued dasatinib, 30 maintained deep molecular responses, and 33 had molecular 
relapses (all during the first 7 months). The authors concluded that a treatment-free period 
lasting for > 1 year is feasible. The DASFREE trial is a study for patients with CML-CP receiving 
either first or subsequent lines of dasatinib who are in stable deep molecular response; the 
primary endpoint is the MMR rate at 12 months after discontinuation.39 An interim analysis of 30 
patients showed that 1 year after discontinuation, patients had a high TFR success rate (63% 
had MMR and molecular relapse-free survival at 12 months).40 There was rescue of molecular 
responses when dasatinib was reinitiated in all patients who relapsed. The STOP-2G-TKI study 
by the French CML group assessed maintenance of MMR following treatment discontinuation in 
patients who received second-generation TKIs (dasatinib or nilotinib) and achieved MR4.5 for the 
previous 2 years or longer.41 TFR rates at 12 and 48 months were 63% and 54%, respectively. 
 
 
Predicting Which Patients Will Benefit From Dasatinib Discontinuation 
Overall, relatively few patients are eligible for a treatment-free period, and not all successfully 
maintain a response following discontinuation. For these patients, reducing dasatinib dosing as 
described above may be the best long-term therapy choice. In deciding which patients to 
include in current TFR trials, investigators considered performance status, age, molecular 
response, mutational profile, and adequate organ function (Table 2). For example, the DADI trial 
examined dasatinib discontinuations in patients who maintained deep molecular response for        
> 1 year.38 Patients with performance status of 0 to 2 and with no severe dysfunction of major 
organ systems were eligible, but patients having BCR-ABL1 mutations associated with dasatinib 
resistance, thus putting them at higher risk for relapse, were not eligible. In the real-life setting, 
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clinicians have been guided by molecular responses (BCR-ABL1 reduction of at least 4 logs, 
sustained for ≥ 2 years) and low Sokal risk score. Among Sokal low-risk patients treated with 
imatinib, 50% to 60% sustained TFR, whereas among high-risk patients, the proportion dropped 
to 10% to 20%.42 
 
Ongoing Trials Investigating Feasibility of Dasatinib Discontinuation 
There are several trials focused on efficacy following discontinuation of dasatinib; these are 
summarized in Table 2 with their full titles and registry numbers. In addition to the trials 
described above with preliminary results published, the D-NewS trial will assess whether 
dasatinib can be discontinued without occurrence of molecular relapse in patients with CML-CP 
in CMR while on dasatinib; the primary outcome is overall probability of maintaining a CMR after 
discontinuing dasatinib.43 The D-STOP trial will evaluate discontinuation of dasatinib for patients 
with CML-CP who maintained CMR for 2 years; the primary outcome measure is the overall 
probability of maintenance of CMR at 12 months after discontinuation.44 The DESTINY trial will 
also evaluate whether patients with CML-CP can discontinue treatment for 24 months while 
maintaining molecular responses.31 The Front-line Treatment of BCR-ABL+ CML with Dasatinib 
(CML1113) trial will follow patients with CML-CP for 5 years after discontinuation of treatment; 
the primary endpoint is the number of patients who permanently discontinue dasatinib.45 The 
LAST (Life After Stopping Tyrosine kinase inhibitors) study will examine the decision-making 
process for patients with CML-CP and physicians who are considering discontinuing dasatinib; 
the primary endpoints are the proportion of patients with CML who develop molecular recurrence 
after discontinuing TKIs, and the patient-reported health status before and after stopping TKIs.46 The 
purpose of the TRAD (Treatment-free Remission Accomplished with Dasatinib) trial is to 
determine whether an operational cure for CML is possible (an operational cure would mean the 
disease no longer requires treatment); the primary endpoint is molecular remission at 12 
months.47 The EURO-SKI (European Stop Tyrosine Kinase Inhibitor) trial will assess duration of 
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MMR following cessation of TKI therapy; patients with CML receiving first- or second-line TKI 
treatment are eligible.48  
 
DISCUSSION 
The treatment of CML is evolving from a landscape where patients were maintained on a TKI 
until failure or resistance occurred to one where initial TKI treatment is induction therapy, which 
in turn may be succeeded by reduced or intermittent dosing as consolidation therapy.42 As the 
life expectancy of patients with CML now approaches that of the general population,3,4 there is 
considerable interest in modifying doses of TKIs, including dasatinib, to mitigate AEs as well as 
to reduce cost burdens for patients and healthcare systems.26 Results of trials designed to 
optimize dasatinib doses for individual patients will help guide future therapy. Accurate and 
timely molecular monitoring should be used to guide dose optimization. ELN and NCCN 
guidelines provide definitions of optimal responses to TKIs and recommendations for molecular 
monitoring.22,23 However, what constitutes a CMR may not be an absolute, as more sensitive 
techniques are validated for future use.49 
Clinical experience with dasatinib dose optimization is still largely unexplored, and thus 
there are questions that remain to be answered. Criteria for when doses should be modified 
have to be established. Currently, the majority of TFR trials require that patients be in molecular 
remission for at least 1 year. However, patients may have residual disease (Ph+ progenitor 
cells) and have yet to relapse.50 In practice, perhaps 50% of patients treated for CML do not 
achieve MR4.5; therefore, it is probably better for patients to receive drug doses that achieve 
remission, then optimize doses for the long term. It is possible that doses resulting in BCR-ABL1 
transcript levels < 1% will be sufficient for some patients. Among imatinib-resistant patients 
treated with either dasatinib or nilotinib, patients with BCR-ABL1 < 1% versus ≥ 1% at 6 months 
had higher 3-year MMR (83% vs 16%, P < .001), PFS (94% vs 84%, P = .05), and OS (94% vs 
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84%, P = .05).51 As trial data mature and are published, the answer to this question should 
become clearer.  
The lowest induction and maintenance doses of dasatinib to achieve optimal responses 
need to be established. Despite what could be considered a short serum half-life (3-5 hours),52 
lower and intermittent doses of dasatinib are proving to be effective treatment options. Beyond 
what long-term studies indicate for induction doses,9,10 patients have been maintained 
successfully on doses as low as 20 mg per day.18 A possible explanation for the efficacy of low-
dose dasatinib may be attributed to its high potency53 and prolonged inhibition of targets.52 For 
example, it has been reported that the mechanism of cellular apoptosis induced by dasatinib is 
comparable between continuous low-dose and transient high-dose treatment in vitro; however, 
the effects on pro-apoptotic molecules (eg, BIM) are prolonged with low-dose (≥6 hours) versus 
high-dose (20 minutes) exposure.52 
The level of efficacy patients should maintain following dose modifications also has yet 
to be determined. Some level of molecular relapse is likely, and re-treatment with a TKI has 
been used successfully.42 Future clinical trials should be designed to determine if administering 
induction followed by maintenance doses of dasatinib is a feasible treatment approach. As a 
word of caution, very long-term follow-up will be required for patients whose doses are modified, 
to ensure they do not relapse. 
How to individualize therapy remains to be explored. As clinical trials do not focus on 
individualized treatment, it is up to clinicians to take into account the needs of the patient: age, 
emerging AEs, or other factors may enter into the decision to modify dosing. It has been our 
experience that a dosing schedule involving weekend holidays (5 days of dasatinib, followed by 
2 days off the drug) has helped to mitigate AEs while maintaining efficacy; also, we have had 
positive experiences with alternate daily dosing. In our collective experience, we have treated  
> 10 patients with modified doses of dasatinib who then maintained their previous response or 
improved from MMR to CMR. Most of these patients started dasatinib at 100 mg per day, and 
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upon achieving MMR, had their daily doses lowered. In some cases, patients started at 70 mg 
per day and achieved MMR, never having received 100 mg per day. For the majority, the 
responses have been durable. Our decisions to reduce doses were based on the molecular 
response achieved by the patient. Even if patients do not yet experience AEs, their doses could 
be lowered to prevent future AEs. This should be considered for special populations, especially 
the elderly.34 
Pharmacogenomics may help determine the optimal dose of dasatinib. As more 
becomes known regarding how genetics affects responses to dasatinib, pharmacogenomics 
may be used in the future to prescribe individualized doses. For example, variations in the P-
glycoprotein allele ABCB1 affected transport of dasatinib, imatinib, and nilotinib into cells, and 
thus have implications for efficacy at a given dose.54 Another study looked at the influence of 
genetic polymorphisms in ABCB1 and ABCG2 (helps confer multidrug resistance), the 
transcription factor Oct1, risk scores (Sokal, EUTOS, and Hasford), and trough concentrations 
of imatinib on CCyR.55 The investigators found that a specific variant in ABCG2 correlated with 
increased CCyR and thus increased survival.55 
 Answers to these questions and others will come from prospective clinical trials. Many 
ongoing trials, as detailed above, are designed to determine how to modify the dose of 
dasatinib, the optimal time to modify dosing, the patients best suited for dose modifications, and 
the level of response that should be maintained on a modified dose. 
 
CONCLUSIONS 
Available data suggest that administering dasatinib below currently approved doses may 
minimize AEs and maintain efficacy. Drug holidays (days of treatment respite) as an alternative 
to dose reductions is another means to mitigate AEs while keeping efficacy high. Maintenance 
therapy (administering a drug at a different dosing schedule in order to maintain a desired level 
of response) may be a suitable treatment goal, and data from current trials should aid in 
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developing guidelines for what maintenance therapy should be. Treatment discontinuation is 
often a goal of CML treatment and certain patients may be well suited to stop dasatinib therapy. 
Close follow-up and dose re-escalation, reinitiation, or switching to another TKI would be 
recommended for patients who demonstrate evidence of disease progression, eg, confirmed 
increase in BCR-ABL1 levels by PCR. Ultimately, treatment decisions will be made through 
discussions between physicians and patients. When to reduce doses, for whom to reduce 
doses, and by how much to reduce doses cannot be settled until data from prospective studies 
have been analyzed. 
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Figure 1. Deaths due to CML relative to approval of TKIs. The number of new CML cases and 
number of deaths due to CML for the years 1992–2013 are shown, with approval of TKIs used 
to treat CML indicated. CML, chronic myeloid leukemia; TKI, tyrosine kinase inhibitors. 
(Reproduced from SEER Cancer Stat Facts: Chronic Myeloid Leukemia (CML), National Cancer 
Institute, Bethesda, MD; http://seer.cancer.gov/statfacts/html/cmyl.html, available in the public 
domain.5) 
 
Figure 2. Deciding when to lower dose based on leukemic burden and BCR-ABL1 transcript 
levels. BCR-ABL1 transcript levels are monitored by real-time quantitative PCR. The 
relationship to transcript levels and possible outcomes is indicated. CCyR, complete cytogenetic 
responses; IS, International Scale; MMR, major molecular response; MR4.5, molecular response 
with 4.5-log reduction of BCR-ABL1 transcripts; PCR, polymerase chain reaction. (Reproduced 
without modification from Morotti A, Fava C, Saglio G. Milestones and monitoring. Curr Hematol 
Malig Rep. 2015;10:167–172. doi 10.1007/s11899-015-0258-1. ©The Authors 2015. Published 
with open access at Springerlink.com under the terms of Creative Commons Attribution 4.0 
International License [CC BY 4.0; https:/ /creativecommons.org/licenses/by/4.0/].19) 
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The focus of CML treatment is shifting to dose management, with the goal of maintaining 
response while improving quality of life. Results obtained from dasatinib dose optimization and 
discontinuation trials will help practitioners determine the best dose and duration of dasatinib for 
patients with CML.  
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Chronic myeloid leukemia (CML) has evolved into a chronic disease managed with tyrosine 
kinase inhibitor (TKI) therapy. Now that long-term survival has been achieved in CML, the focus 
of treatment shifts to dose optimization, with the goal of maintaining response while improving 
quality of life. In this review, we discuss optimizing the dose of the second-generation TKI 
dasatinib. Once-daily dosing regimens for dasatinib in the first and later lines of treatment were 
established through long-term (5- and 7-year) trials. Recently published data indicate that 
further dose optimization may maintain efficacy while minimizing adverse events. Results 
obtained from dose optimization and discontinuation trials currently in progress will help 
practitioners determine the best dose and duration of dasatinib for patients with CML, as 
treatment decisions will be made through continued discussions between physicians and 
patients.  
 
KEYWORDS: Dasatinib; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Quality of life;  
Tyrosine kinase inhibitor; Dose optimization
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Chronic myeloid leukemia (CML) has evolved into a chronic disease now managed with tyrosine 
kinase inhibitor (TKI) therapy.1,2 As a result of the use of TKIs approved for CML, patients 
diagnosed in 2013 are predicted to lose < 3 life-years compared with those without CML, and 
thus have life spans approaching those of the general population.3,4 In the United States, rates 
for new CML cases have been stable over the past 10 years; however, death rates have been 
decreasing an average 3.1% each year over 2004 through 2013 (Fig. 1).5 Sixty-five percent of 
patients with CML survived 5 years or more during 2006 through 2012, as opposed to the 5-
year period ending in 2000, when < 50% of patients survived 5 years or more. 
Now that long-term survival has been achieved in CML, the focus of treatment shifts to dose 
optimization and personalization. Dasatinib is a second-generation BCR-ABL1 kinase inhibitor, 
currently approved at 2 doses6: at 100 mg once daily for patients with CML in chronic phase 
(CML-CP), newly diagnosed or following resistance or intolerance to a previous therapy, and at 
140 mg once daily for patients with CML in accelerated/blast phase (CML-AP/BP) or with 
Philadelphia chromosome-positive (Ph+) acute lymphocytic leukemia who are resistant or 
intolerant to prior therapy. Optimization of dasatinib dosing should have 2 goals: maintenance of 
cytogenetic and molecular responses, and minimization of adverse events (AEs). In particular, 
optimization should describe the minimum daily dose of dasatinib that can sustain remission 
and achieve a patient’s therapeutic goals.  
Maintaining or improving quality of life (QoL) for patients with CML over the course of their 
treatment should be a major part of minimizing AEs. QoL may influence a patient’s decision to 
seek treatment regimens of dasatinib that balance efficacy with the fewest AEs, and also offer 
the easiest adherence.7 For example, a drug taken once per day is preferable to one requiring 
multiple daily doses, and a drug that may be taken regardless of type or timing of food is 
preferable to one that requires timing with regard to meals or that cannot be taken with certain 
foods. Younger female patients with CML treated with imatinib have reported lower QoL than 
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the general population8; this finding implies that for those who anticipate being on a TKI for 
many years, QoL aspects of treatment may be especially important. 
Ongoing studies are helping to refine treatment options that may be appropriate for some 
patients, including dasatinib dose reductions, interruptions, or discontinuation. It is the goal of 
this review to bring clarity to the field of dasatinib dose optimization by discussing published 
retrospective analyses and ongoing prospective studies. In particular, we discuss factors that 
drive selection of the optimal dasatinib dose and duration for the treatment of CML. 
 
OPTIMIZING CURRENTLY APPROVED DOSES FOR DASATINIB 
The currently approved doses of dasatinib resulted from 2 long-term pivotal trials aimed at 
maximizing efficacy while minimizing AEs. The CA180-034 trial enrolled patients with imatinib-
resistant or -intolerant CML-CP.9 This study compared dasatinib 100 or 140 mg per day, and 
once- or twice-daily schedules, to determine the optimal dosage and regimen. Results showed 
that dasatinib treatment at a dose of 100 mg once daily demonstrated durable efficacy and a 
tolerable long-term safety profile. The data obtained from this study should be considered the 
proof of principle that the daily dose of dasatinib can be lowered, from 70 mg twice per day (a 
total dose of 140 mg per day) to 100 mg once per day in particular, while maintaining efficacy in 
patients intolerant of or resistant to imatinib. 
The CA180-056 DASISION trial (Dasatinib Versus Imatinib Study in Treatment-Naïve 
Chronic Myeloid Leukemia Patients) was a study of newly diagnosed patients with CML-CP who 
received dasatinib 100 mg once daily or imatinib 400 mg once daily for a minimum of 5 years.10 
At the end of DASISION, dasatinib 100 mg once daily continued to show improved efficacy 
compared with imatinib 400 mg daily in the first line. The safety profile of first-line dasatinib            
100 mg once daily was well tolerated over the long term; no new safety signals were reported. 
Taken together, the results of DASISION confirmed that 100 mg once daily constitutes an 
optimal dose of dasatinib for patients newly diagnosed with CML-CP. 
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DASATINIB DOSE REDUCTIONS AND/OR INTERRUPTIONS 
Efficacy and Safety 
There are published data indicating that modifying the dasatinib dose from 100 mg once daily 
can mitigate significant AEs yet maintain efficacy over the long term. In the phase II DARIA-01 
study, patients with CML-CP were enrolled to determine factors influencing adherence and 
efficacy when AEs from dasatinib were managed with dose modifications.11 Patients had their 
dasatinib doses reduced from 100 mg per day to 50 mg per day when they experienced a grade 
2 or worse nonhematologic AE or grade 3 or worse hematologic AE. In this small study, 25% of 
patients had their doses reduced in the first 3 months, and 34% had their doses reduced in the 
first 6 months. At 6 months, 25 patients (78%) achieved complete cytogenetic responses 
(CCyR) and 13 (40%) achieved a major molecular response (MMR). Additionally, pleural 
effusions were managed effectively through dose modifications while molecular responses were 
maintained. In a small phase II study, NordCML006, 9 patients who had dasatinib doses 
reduced (6 to an average of 50 mg per day and 3 to an average of 63 mg per day) had nearly 
the same median rate of molecular response with 4.5-log reduction of BCR-ABL1 transcripts 
(MR4.5) as did the 8 patients who were maintained on 100 mg per day (P = .53).12 
Previously, a retrospective analysis of exposure and response to dasatinib in the CA180-
034 trial showed that major cytogenetic response (MCyR) was significantly associated with 
average steady-state dasatinib plasma concentrations.13 Reducing the daily dose from 70 mg 
twice daily to 100 mg once daily minimized AEs while maintaining efficacy by exploiting 
differences in measures of exposure: the 100 mg once-daily arm had the lowest steady-state 
trough concentration of the 4 dose arms investigated in CA180-034. Although this arm also had 
the lowest weighted average steady-state dasatinib plasma concentration, it had the highest 
dose maintenance and efficacy. Moreover, pleural effusion was significantly associated with 
trough concentration, and thus occurred the least in the 100 mg once-daily arm.  
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The first-line OPTIMDASATINIB (Optimized Tyrosine Kinase Inhibitors Monotherapy) 
trial is currently the only prospective study of dose optimization based on therapeutic drug 
monitoring.14 This is a phase II trial with 289 newly diagnosed patients with CML-CP enrolled to 
validate a dose-optimization strategy using plasma levels of dasatinib. As part of the study, 
patients with high minimal plasma concentrations (Cmin ≥ 3 nmol/L) had their dasatinib doses 
reduced in 20-mg decrements every 15 days to 40 mg per day (if needed) in order to lower Cmin 
to < 3 nmol/L. Preliminary results of OPTIMDASATINIB showed that patients allocated to this 
therapeutic drug monitoring strategy showed reduced risk of pleural effusion without impairment 
of the kinetics of response. By 24 months, 88% of the patients with high Cmin values who then 
had their dasatinib doses lowered achieved MMR, 69% achieved molecular response with 4-log 
reduction of BCR-ABL1 transcripts (MR4.0), and 39% achieved MR4.5, considered a complete 
molecular response/remission (CMR). Moreover, the dose-optimization strategy reduced the 
risk of pleur l effusion in the study population, consistent with the data obtained by Wang et al 
in their retrospective analysis described above.13,14  
Intermittent dosing with dasatinib has been shown to improve tolerability in patients with 
CML who were resistant to or intolerant of imatinib.15 A strategy of 3 to 5 days of dasatinib, 
followed by 2 to 4 days of no drug, reduced toxicity while maintaining efficacy. Overall, 18 of 31 
patients (58%) maintained or had improved response while on weekly treatment, and 16 of 18 
(89%) achieved MMR or MR4.5. A larger study wherein 176 patients with CML received reduced 
and/or interrupted dosing of dasatinib or nilotinib showed there was no statistically significant 
difference between rates of MCyR or CCyR.16 The median lowest dasatinib doses given in        
this study were 60 mg per day for patients with CML-CP and 80 mg per day for patients with 
CML-AP.  
In addition, several case reports have corroborated the results of the previously 
discussed studies. In one report, a patient aged 85 years was successfully treated with 20 mg of 
dasatinib twice weekly after developing liver dysfunction on imatinib and achieved MMR 24 
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months later.17 In another report, 2 patients with CML-CP were treated with 20 to 50 mg per day 
of dasatinib; 1 maintained undetectable BCR-ABL1 transcripts for up to 1 year and 1 had levels 
of BCR-ABL1 transcripts 4 to 5 logs reduced (at times the levels were undetectable).18 
It has been our experience that a dosing schedule involving weekend holidays (5 days of 
dasatinib, followed by 2 days off the drug) has helped to mitigate AEs while maintaining efficacy; 
also, we have had positive experiences with alternate daily dosing. In our collective experience, 
we have treated > 10 patients with modified doses of dasatinib who then maintained their 
previous response or improved from MMR to complete molecular response (CMR). Most of 
these patients started dasatinib at 100 mg per day, and upon achieving MMR, had their daily 
doses lowered. In some cases, patients started at 70 mg per day and achieved MMR, never 
having received 100 mg per day. For the majority, the responses have been durable. Our 
decisions to reduce doses were based on the molecular response achieved by the patient. 
 
Predicting Which Patients Will Benefit From Dose Reductions 
Early molecular responses to a TKI (within the first 6 months of initiating treatment) are 
predictive of long-term outcomes in CML, and several studies have shown that TKIs induced 
fast and deep molecular responses, defined as MR4.0 or even MR4.5.19-21 These levels of 
responses predict durable, stable responses, and are considered prerequisites for either dose 
reductions or dose interruptions.  
Both the European LeukemiaNet (ELN) and National Comprehensive Cancer Care 
Network (NCCN) recommendations define optimal responders in terms of molecular 
responses.19,22,23 Therefore, at least for some patients, if deep molecular responses (MR4.0 or 
MR4.5) have been achieved after a treatment period, it should be possible to reduce dasatinib 
doses (Fig. 2).19 However, molecular monitoring at fixed intervals is recommended by both the 
NCCN (every 3-6 months 2 years after the achievement of CCyR)22 and the ELN (after the 
achievement of MMR) recommend molecular monitoring at fixed intervals,22,23 which may result 
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in missing the optimal time to reduce doses of dasatinib. For example, if a deep response 
occurs early in this timeframe between tests,, the opportunity for a dose reduction may be 
missed or delayed. 
Final study results from the 5-year DASISION trial for patients with CML-CP who 
received first-line dasatinib confirmed that achieving an early molecular response, BCR-ABL1   
≤ 10% International Scale (IS) at 3 months, was correlated with significantly higher progression-
free survival (PFS) and overall survival (OS) rates (88.9% and 93.8%, respectively, for PFS and 
OS) compared with patients who achieved BCR-ABL1 > 10% (IS) at 3 months (71.8% and 
80.6%, respectively, for PFS and OS).10 For patients who received dasatinib after failing or 
becoming intolerant to imatinib in the 7-year CA180-034 study, those who achieved BCR-ABL1 
≤ 10% (IS) at 3 months likewise showed significantly higher PFS and OS (56% and 72%, 
respectively, for PFS and OS) than those who had BCR-ABL1 > 10% (IS) at 3 months (21% and 
56%, respectively, for PFS and OS).9 
Tools predicting outcome at any time during and after therapy would be useful 
throughout a patient’s treatment regimen. Using data from DASISION and CA180-034,9,10 
investigators predicted responses during treatment with dasatinib based on plotting BCR-ABL1 
transcript levels and PFS or OS of patient populations.24 Such analyses may allow investigators 
to predict future outcomes at any time, rather than solely at times of BCR-ABL1 monitoring. A 
limitation of these projections would be that they become less precise as more time elapses 
from initiation of TKI therapy: the number of patients for whom a prediction might be made 
diminishes, reducing the accuracy of the prediction. Increasing the number of patients in the 
cohort is one way to negate this limitation, for example by combining suitable datasets.  
In addition to molecular responses, effects on CD34+ cells may provide another means 
to predict responses to dasatinib. A study of newly diagnosed patients with CML-CP showed 
that the molecular responses at 3 and 6 months depended on the time of dasatinib plasma 
levels above the IC50 for CD34+ cells (dasatinib concentration required to inhibit 50% of CD34+ 
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cells).25 It was found that patients with longer times (> 12 hours) above the IC50 had significantly 
better prognoses: molecular responses at 3 and < 4 log reductions were 50% and 45%, 
respectively.  
 
Other Patient Factors 
Patient preference should be taken into consideration when deciding to modify dasatinib doses. 
Reductions and/or interruptions may be preferred by patients when discontinuing dasatinib is 
not an option; administering a lower dose of dasatinib, after starting treatment at the approved 
dose, may be preferable to switching to another TKI.16 Moreover, modifying doses (lowering or 
interrupting) to mitigate toxicity may help improve adherence.11 
In addition to minimizing AEs, economic concerns may drive a decision to lower daily 
doses for some patients.26 In one study, 41 patients with CML-CP were treated with a mean 
dose of das tinib of 92 mg ± 23 mg per day while achieving and maintaining efficacy, although 
the quality of the responses was not reported.26 The driving force for reducing doses in this 
study appears to have been financial, rather than reduction of AEs. Furthermore, as long-term 
survival of patients with CML is predicted to increase the prevalence of the disease in the near 
future, the burden of healthcare costs may have to be considered when planning treatment. 
Thus, economic considerations beyond the personal may play a role in seeking the lowest 
effective dose of dasatinib or of any TKI.27 Many of these cost concerns may be mitigated in the 
future, as approved generic versions of TKIs become available. 
 
Ongoing Trials Investigating Dasatinib Efficacy With Dose Optimization 
Nine trials are currently under way, focusing on modifying dasatinib dosing while retaining 
efficacy; their full titles, registry numbers, and summaries are given in Table 1. Two of these 
studies, DARIA-0111 and OPTIMDASATINIB,28 and have reported preliminary data and are 
described above.  
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There are 4 studies under way to determine optimizing dasatinib doses in patients or 
patient subgroups. A low-dose study in Japan will evaluate efficacy of 50 mg dasatinib per day 
in patients who are resistant to or intolerant of low-dose imatinib; the primary outcome measure 
is MMR at 12 months.29 The CML12 DIRECT (Dasatinib Intensity Regulation to Eliminate 
Cumulative Toxicities) study will examine dose optimization of dasatinib in patients 60 years and 
older with CML. In this study, therapeutic daily monitoring will be used to optimize effective 
doses with minimal toxicity.30 The DESTINY (De-Escalation and Stopping Treatment of Imatinib, 
Nilotinib or sprYcel) trial will evaluate efficacy at 50 mg per day of dasatinib in treatment-naive 
patients with CML-CP31; its primary outcome is the proportion of patients who maintain MMR on 
50 mg per day for 12 months. Patients will then discontinue dasatinib for up to 24 months. The 
Therapy of Early Chronic Phase Chronic Myelogenous Leukemia With Dasatinib trial will 
evaluate whether giving 50 mg dasatinib per day to patients with early CML-CP is as effective 
as giving 100 mg per day.32  
Two studies will examine dasatinib efficacy with planned dose interruptions. The 
DasaHIT trial will evaluate dasatinib holidays for improved drug tolerance in treatment-naive 
patients with CML and in patients receiving dasatinib as second-line treatment; its primary 
outcome measures are cumulative toxicity after 2 years and MMR as assessed by monitoring 
BCR-ABL1 transcripts at 2 years.33 The Optimization of TKIs Treatment and Quality of Life trial 
will evaluate the efficacy of intermittent dasatinib dosing (1 month on, 1 month off vs 1 month 
on, 1 month off in year 1; 1 month on, 2 months off in year 2; 1 month on, 3 months off in year 
3), and the effect on QoL such dosing regimens may have; the primary outcome is changes in 
QoL at defined times.34  
Finally, the DasPAQT (Treating Patients With Chronic Myeloid Leukemia in Chronic Phase 
With Dasatinib) trial is a real-life study to gather data on how CML is managed with dasatinib in 
practices outside of academic settings, including whether and when dose reductions are used.35 
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Treatment-free remission (TFR), defined as being free from molecular relapse following TKI 
discontinuation,22 is currently an unmet need of CML therapy, as TKIs have increased patients’ 
life spans to be nearly equal to those of the general population.3,4 To date, there are limited 
published data on discontinuing dasatinib. In 1 small trial of 34 patients with CML-CP, second-
generation TKIs (dasatinib and nilotinib) were safely discontinued.36 The 12-month probability of 
maintaining table MMR was 58%, and no patient progressed to CML-AP or experienced 
hematologic relapse. The OPTIMDASATINIB trial for newly diagnosed patients with CML also 
examined dose discontinuations in early responders (those who had BCR-ABL1 [IS] ≤ 0.0032% 
by 3 years).37 Preliminary results showed that at 12 months, 41% of patients were in TFR. The 
DADI trial evaluated the effect of dasatinib discontinuation in patients with CML who had been in 
deep molecular response for at least 1 year.38 Preliminary results showed that of the 63 patients 
who discontinued dasatinib, 30 maintained deep molecular responses, and 33 had molecular 
relapses (all during the first 7 months). The authors concluded that a treatment-free period 
lasting for > 1 year is feasible. The DASFREE trial is a study for patients with CML-CP receiving 
either first or subsequent lines of dasatinib who are in stable deep molecular response; the 
primary endpoint is the MMR rate at 12 months after discontinuation.39 An interim analysis of 30 
patients showed that 1 year after discontinuation, patients had a high TFR success rate (63% 
had MMR and molecular relapse-free survival at 12 months).40 There was rescue of molecular 
responses when dasatinib was reinitiated in all patients who relapsed. The STOP-2G-TKI study 
by the French CML group assessed maintenance of MMR following treatment discontinuation in 
patients who received second-generation TKIs (dasatinib or nilotinib) and achieved MR4.5 for the 
previous 2 years or longer.41 TFR rates at 12 and 48 months were 63% and 54%, respectively. 
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Predicting Which Patients Will Benefit From Dasatinib Discontinuation 
Overall, relatively few patients are eligible for a treatment-free period, and not all successfully 
maintain a response following discontinuation. For these patients, reducing dasatinib dosing as 
described above may be the best long-term therapy choice. In deciding which patients to 
include in current TFR trials, investigators considered performance status, age, molecular 
response, mutational profile, and adequate organ function (Table 2). For example, the DADI trial 
examined dasatinib discontinuations in patients who maintained deep molecular response for        
> 1 year.38 Patients with performance status of 0 to 2 and with no severe dysfunction of major 
organ systems were eligible, but patients having BCR-ABL1 mutations associated with dasatinib 
resistance, thus putting them at higher risk for relapse, were not eligible. In the real-life setting, 
clinicians have been guided by molecular responses (BCR-ABL1 reduction of at least 4 logs, 
sustained for ≥ 2 years) and low Sokal risk score. Among Sokal low-risk patients treated with 
imatinib, 50% to 60% sustained TFR, whereas among high-risk patients, the proportion dropped 
to 10% to 20%.42 
 
Ongoing Trials Investigating Feasibility of Dasatinib Discontinuation 
There are several trials focused on efficacy following discontinuation of dasatinib; these are 
summarized in Table 2 with their full titles and registry numbers. In addition to the trials 
described above with preliminary results published, the D-NewS trial will assess whether 
dasatinib can be discontinued without occurrence of molecular relapse in patients with CML-CP 
in complete molecular remissionCMR while on dasatinib; the primary outcome is overall 
probability of maintaining CMR after discontinuing dasatinib.43 The D-STOP trial will evaluate 
discontinuation of dasatinib for patients with CML-CP who maintained CMR for 2 years; the 
primary outcome measure is the overall probability of maintenance of CMR at 12 months after 
discontinuation.44 The DESTINY trial will also evaluate whether patients with CML-CP can 
discontinue treatment for 24 months while maintaining molecular responses.31 The Front-line 
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Treatment of BCR-ABL+ CML with Dasatinib (CML1113) trial will follow patients with CML-CP 
for 5 years after discontinuation of treatment; the primary endpoint is the number of patients 
who permanently discontinue dasatinib.45 The LAST (Life After Stopping Tyrosine kinase 
inhibitors) study will examine the decision-making process for patients with CML-CP and 
physicians who are considering discontinuing dasatinib; the primary endpoints are the proportion 
of patients with CML who develop molecular recurrence after discontinuing TKIs, and the patient-
reported health status before and after stopping TKIs.46 The purpose of the TRAD (Treatment-free 
Remission Accomplished with Dasatinib) trial is to determine whether an operational cure for 
CML is possible (an operational cure would mean the disease no longer requires treatment); the 
primary endpoint is molecular remission at 12 months.47 The EURO-SKI (European Stop 
Tyrosine Kinase Inhibitor) trial will assess duration of MMR following cessation of TKI therapy; 
patients with CML receiving first- or second-line TKI treatment are eligible.48  
 
DISCUSSION 
The treatment of CML is evolving from a landscape where patients were maintained on a TKI 
until failure or resistance occurred to one where initial TKI treatment is induction therapy, which 
in turn may be succeeded by reduced or intermittent dosing as consolidation therapy.42 As the 
life expectancy of patients with CML now approaches that of the general population,3,4 there is 
considerable interest in modifying doses of TKIs, including dasatinib, to mitigate AEs as well as 
to reduce cost burdens for patients and healthcare systems.26 Results of trials designed to 
optimize dasatinib doses for individual patients will help guide future therapy. Accurate and 
timely molecular monitoring should be used to guide dose optimization. ELN and NCCN 
guidelines provide definitions of optimal responses to TKIs and recommendations for molecular 
monitoring.22,23 However, what constitutes a complete molecular responseCMR may not be an 
absolute, as more sensitive techniques are validated for future use.49 
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Clinical experience with dasatinib dose optimization is still largely unexplored, and thus 
there are questions that remain to be answered. Criteria for when doses should be modified 
have to be established. Currently, the majority of TFR trials require that patients be in molecular 
remission for at least 1 year. However, patients may have residual disease (Ph+ progenitor 
cells) and have yet to relapse.50 In practice, perhaps 50% of patients treated for CML do not 
achieve MR4.5; therefore, it is probably better for patients to receive drug doses that achieve 
remission, then optimize doses for the long term. It is possible that doses resulting in BCR-ABL1 
transcript levels < 1% will be sufficient for some patients. Among imatinib-resistant patients 
treated with either dasatinib or nilotinib, patients with BCR-ABL1 < 1% versus ≥ 1% at 6 months 
had higher 3-year MMR (83% vs 16%, P < .001), PFS (94% vs 84%, P = .05), and OS (94% vs 
84%, P = .05).51 As trial data mature and are published, the answer to this question should 
become clearer.  
The lowest induction and maintenance doses of dasatinib to achieve optimal responses 
need to be established. Despite what could be considered a short serum half-life (3-5 hours),52 
lower and intermittent doses of dasatinib are proving to be effective treatment options. Beyond 
what long-term studies indicate for induction doses,9,10 patients have been maintained 
successfully on doses as low as 20 mg per day.18 A possible explanation for the efficacy of low-
dose dasatinib may be attributed to its high potency53 and prolonged inhibition of targets.52 For 
example, it has been reported that the mechanism of cellular apoptosis induced by dasatinib is 
comparable between continuous low-dose and transient high-dose treatment in vitro; however, 
the effects on pro-apoptotic molecules (eg, BIM) are prolonged with low-dose (≥6 hours) versus 
high-dose (20 minutes) exposure.52 
The level of efficacy patients should maintain following dose modifications also has yet 
to be determined. Some level of molecular relapse is likely, and re-treatment with a TKI has 
been used successfully.42 Future clinical trials should be designed to determine if administering 
induction followed by maintenance doses of dasatinib is a feasible treatment approach. As a 
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word of caution, very long-term follow-up will be required for patients whose doses are modified, 
to ensure they do not relapse. 
How to individualize therapy remains to be explored. As clinical trials do not focus on 
individualized treatment, it is up to clinicians to take into account the needs of the patient: age, 
emerging AEs, or other factors may enter into the decision to modify dosing. It has been our 
experience that a dosing schedule involving weekend holidays (5 days of dasatinib, followed by 
2 days off the drug) has helped to mitigate AEs while maintaining efficacy; also, we have had 
positive experiences with alternate daily dosing. In our collective experience, we have treated  
> 10 patients with modified doses of dasatinib who then maintained their previous response or 
improved from MMR to CMR. Most of these patients started dasatinib at 100 mg per day, and 
upon achieving MMR, had their daily doses lowered. In some cases, patients started at 70 mg 
per day and achieved MMR, never having received 100 mg per day. For the majority, the 
responses h ve been durable. Our decisions to reduce doses were based on the molecular 
response achieved by the patient. Even if patients do not yet experience AEs, their doses could 
be lowered to prevent future AEs. This should be considered for special populations, especially 
the elderly.34 
Pharmacogenomics may help determine the optimal dose of dasatinib. As more 
becomes known regarding how genetics affects responses to dasatinib, pharmacogenomics 
may be used in the future to prescribe individualized doses. For example, variations in the P-
glycoprotein allele ABCB1 affected transport of dasatinib, imatinib, and nilotinib into cells, and 
thus have implications for efficacy at a given dose.52 54 Another study looked at the influence of 
genetic polymorphisms in ABCB1 and ABCG2 (helps confer multidrug resistance), the 
transcription factor Oct1, risk scores (Sokal, EUTOS, and Hasford), and trough concentrations 
of imatinib on CCyR.53 55 The investigators found that a specific variant in ABCG2 correlated 
with increased CCyR and thus increased survival.5355 
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 Answers to these questions and others will come from prospective clinical trials. Many 
ongoing trials, as detailed above, are designed to determine how to modify the dose of 
dasatinib, the optimal time to modify dosing, the patients best suited for dose modifications, and 
the level of response that should be maintained on a modified dose. 
 
CONCLUSIONS 
Available data suggest that administering dasatinib below currently approved doses may 
minimize AEs and maintain efficacy. Drug holidays (days of treatment respite) as an alternative 
to dose reductions is another means to mitigate AEs while keeping efficacy high. Maintenance 
therapy (administering a drug at a different dosing schedule in order to maintain a desired level 
of response) may be a suitable treatment goal, and data from current trials should aid in 
developing guidelines for what maintenance therapy should be. Treatment discontinuation is 
often a goal of CML treatment and certain patients may be well suited to stop dasatinib therapy. 
Close follow-up and dose re-escalation, reinitiation, or switching to another TKI would be 
recommended for patients who demonstrate evidence of disease progression, eg, confirmed 
increase in BCR-ABL1 levels by PCR. Ultimately, treatment decisions will be made through 
discussions between physicians and patients. When to reduce doses, for whom to reduce 
doses, and by how much to reduce doses cannot be settled until data from prospective studies 
have been analyzed. 
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Figure 1. Deaths due to CML relative to approval of TKIs. The number of new CML cases and 
number of deaths due to CML for the years 1992–2013 are shown, with approval of TKIs used 
to treat CML indicated. CML, chronic myeloid leukemia; TKI, tyrosine kinase inhibitors. 
(Reproduced from SEER Cancer Stat Facts: Chronic Myeloid Leukemia (CML), National Cancer 
Institute, Bethesda, MD; http://seer.cancer.gov/statfacts/html/cmyl.html, available in the public 
domain.5) 
 
Figure 2. Deciding when to lower dose based on leukemic burden and BCR-ABL1 transcript 
levels. BCR-ABL1 transcript levels are monitored by real-time quantitative PCR. The 
relationship to transcript levels and possible outcomes is indicated. CCyR, complete cytogenetic 
responses; IS, International Scale; MMR, major molecular response; MR4.5, molecular response 
with 4.5-log reduction of BCR-ABL1 transcripts; PCR, polymerase chain reaction. (Reproduced 
without modification from Morotti A, Fava C, Saglio G. Milestones and monitoring. Curr Hematol 
Malig Rep. 2015;10:167–172. doi 10.1007/s11899-015-0258-1. ©The Authors 2015. Published 
with open access at Springerlink.com under the terms of Creative Commons Attribution 4.0 
International License [CC BY 4.0; https:/ /creativecommons.org/licenses/by/4.0/].19) 
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TABLE 2. Ongoing Clinical Trials for Discontinuations of Dasatinib 
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Figure 1. Deaths due to CML relative to approval of TKIs. The number of new CML cases and number of 
deaths due to CML for the years 1992–2013 are shown, with approval of TKIs used to treat CML indicated. 
CML, chronic myeloid leukemia; TKI, tyrosine kinase inhibitors. (Reproduced from SEER Cancer Stat Facts: 
Chronic Myeloid Leukemia (CML), National Cancer Institute, Bethesda, MD; 
http://seer.cancer.gov/statfacts/html/cmyl.html, available in the public domain.5)  
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Figure 2. Deciding when to lower dose based on leukemic burden and BCR-ABL1 transcript levels. BCR-ABL1 
transcript levels are monitored by real-time quantitative PCR. The relationship to transcript levels and 
possible outcomes is indicated. CCyR, complete cytogenetic responses; IS, International Scale; MMR, major 
molecular response; MR4.5, molecular response with 4.5-log reduction of BCR-ABL1 transcripts; PCR, 
polymerase chain reaction. (Reproduced without modification from Morotti A, Fava C, Saglio G. Milestones 
and monitoring. Curr Hematol Malig Rep. 2015;10:167–172. doi 10.1007/s11899-015-0258-1. ©The 
Authors 2015. Published with open access at Springerlink.com under the terms of Creative Commons 
Attribution 4.0 International License [CC BY 4.0; https:/ /creativecommons.org/licenses/by/4.0/].19)  
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